FDA approves biosimilar ogivri for breast, stomach cancers
(HealthDay)—Ogivri (trastuzumab-dkst) has been approved by the U.S. Food and Drug Administration as the nation's first biosimilar drug to treat certain breast and stomach cancers, the agency said Friday in a news release.
Dec 4, 2017
0
0